Securities Code: 002898
Securities Abbreviation: Sailong Delisting
Announcement No.: 2026-078
Sailong Pharmaceutical Group Co., Ltd.
Sixth Risk Warning Announcement on Company Stock Entering Delisting Stage Trading
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and there are no false records, misleading statements, or material omissions.
Special Risk Warning:
-
Sailong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") stock will be delisted on the next trading day after the delisting stage ends, and the company's stock will be terminated from listing.
-
The company's stock resumed trading and entered the delisting stage on June 26, 2026. The delisting stage will last for fifteen trading days, with the expected last trading day being July 16, 2026. This announcement is disclosed on the thirteenth trading day. With two remaining trading days, the stock will be terminated from listing upon the expiration of the trading period. Investors are kindly requested to invest prudently and pay attention to risks.
-
During the trading period of the company's stock in the delisting stage, the company will not plan or implement major asset restructurings.
-
Investors, securities companies, and other market participants are requested to settle stock pledge repurchase, agreed repurchase, margin financing, securities lending, and other businesses in a timely manner before the stock delisting.
-
For judicial freezing businesses that expire after the stock delisting and before the initial registration period of the two-network company and delisted company board (hereinafter referred to as the "Delisting Board") managed by Shenzhen Securities Transfer Co., Ltd. on behalf of the original securities company, it is recommended that the competent authorities complete the renewal of the freezing procedures through the original assisting execution channels before the stock delisting.